Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00112294
Status:
COMPLETED
Last Update Posted:
2015-12-24
First Post:
2005-06-01
Brief Title:
Study of TaxaneCarboplatin - Cetuximab as First-Line Treatment for Patients With AdvancedMetastatic Non-Small Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Multicenter Phase III Study of TaxaneCarboplatinCetuximab Versus TaxaneCarboplatin as First-Line Treatment for Patients With AdvancedMetastatic Non-Small Cell Lung Cancer
Status:
COMPLETED
Status Verified Date:
2015-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this clinical research study is to learn if patients treated with the combination of TaxaneCarboplatin plus Cetuximab CTC have a longer progression-free survival than patients treated with TaxaneCarboplatin TC alone The safety of this treatment will also be studied
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None